Clinical evidence supports this hypothesis, as reduced levels of ApoA-I have been associated with earlier onset of PD and increased motor severity, suggesting its potential utility as a biomarker for disease progression [114,115]. The gene discussed is APOA1; the disease is Parkinson disease.